IP Group and V-Bio have backed a round that will support phase 2 trials for a treatment for diabetic macular edema.

Oxular, a UK-based retinal therapeutics developer, received $37m in a funding round yesterday backed by commercialisation firm IP Group and V-Bio Ventures, a venture fund affiliated with VIB.
Venture capital firm Forbion Capital Partners led the round, which also featured investment firm NeoMed.
Founded in 2014 as Precision Ocular, Oxular is developing therapies for retinal disease. Its drug administration technology is able to continuously deliver formulations over the course of up to a year and directly to the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in